Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

CRISPR uncovers gene that supercharges vitamin D—and stops tumors in their tracks

A gene called SDR42E1 has been identified as a key player in how our bodies absorb and process vitamin D. Researchers found that disabling this gene in colorectal cancer cells not only crippled their survival but also disrupted thousands of other genes tied to cancer and metabolism. This opens the door to highly targeted cancer therapies—by either cutting off vitamin D supply to tumors or enhancing the gene’s activity to boost health. The findings hint at vast possibilities in treating diseases influenced by vitamin D, though long-term impacts remain uncertain.

Study reveals hidden regulatory roles of ‘junk’ DNA

A new international study suggests that ancient viral DNA embedded in our genome, which were long dismissed as genetic “junk,” may actually play powerful roles in regulating gene expression. Focusing on a family of sequences called MER11, researchers from Japan, China, Canada, and the US have shown that these elements have evolved to influence how genes turn on and off, particularly in early human development.

The findings are published in the journal Science Advances.

Transposable elements (TEs) are repetitive DNA sequences in the genome that originated from ancient viruses. Over millions of years, they spread throughout the genome via copy-and-paste mechanisms.

A common food additive solves a sticky neuroscience problem

An interdisciplinary team working on balls of human neurons called organoids wanted to scale up their efforts and take on important new questions. The solution was all around them.

For close to a decade now, the Stanford Brain Organogenesis Program has spearheaded a revolutionary approach to studying the brain: Rather than probe intact brain tissues in humans and other animals, they grow three-dimensional brain-like tissues in the lab from , creating models called human neural organoids and assembloids.

Beginning in 2018 as a Big Ideas in Neuroscience project of Stanford’s Wu Tsai Neurosciences Institute, the program has brought together neuroscientists, chemists, engineers, and others to tackle the neural circuits involved in pain, genes that drive neurodevelopmental disorders, new ways to study brain circuits, and more.

‘Standard candle’ particle measurement enables hunt for hybrid mesons

A rather unassuming particle is playing an important role in the hunt for subatomic oddities. Similar to protons and neutrons, mesons are composed of quarks bound together by the strong nuclear force. But these short-lived particles have different characteristics that can reveal new information about the atomic nucleus and how the universe works.

Advancing this understanding could one day enable new discoveries in many fields, ranging from nuclear power to medicine and materials engineering.

The so-called a2 meson is a relatively lightweight system of quarks. It is produced in experiments at the U.S. Department of Energy’s Thomas Jefferson National Accelerator Facility.

Different Bacterial Genes Have Different Turn-Ons

Not all genes respond in the same way to regulation by the same molecule—a property that might enable cells to produce complex genetic responses.

Genes in living cells may become active or may be suppressed in response to environmental stimuli such as heat or the availability of nutrients. For bacteria, this gene regulation often appears to be a simple “on-off switch” controlled by regulatory proteins called transcription factors (TFs). But researchers have now found that different genes might respond differently to the same stimulus even if they are regulated by the same TF [1]. The team activated genes involved in DNA repair and observed gene-to-gene variations in their protein production patterns. Such differences might have been exploited by evolution to achieve complex responses with relatively few molecular components, the researchers suggest.

In the typical scenario, a TF binds to a region of a so-called promoter, a DNA sequence next to a gene. If the TF is the type that blocks gene expression, it prevents the enzyme RNA polymerase from binding and thus from beginning the process of producing the protein that the gene encodes. Because of thermal fluctuations (noise), the TF may spontaneously unbind, allowing gene expression to proceed until it rebinds. The rate of TF binding depends on its concentration, so fluctuations in concentration will cause changes in gene expression.

Extracellular vesicles from antler blastema progenitor cells reverse bone loss and mitigate aging-related phenotypes in mice and macaques

Antler blastema progenitor cells (ABPCs) are a distinct population of skeletal mesenchymal stem cells found in regenerating deer antlers, with strong stemness and renewal capacity in vitro. Stem cell-derived extracellular vesicles (EVs) are emerging as potential therapeutic candidates that can mediate donor cells’ beneficial effects. Here, we tested the effects of ABPC-derived EVs (EVsABPC) on aging in mice and rhesus macaques (Macaca mulatta). We identified a variety of unique factors in EVsABPC and showed that in vitro, EVsABPC attenuated phenotypes of senescence in bone marrow stem cells. In aged mice and macaques, EVsABPC substantially increased femoral bone mineral density. Further, intravenous EVsABPC improved physical performance, enhanced cognitive function and reduced systemic inflammation in aged mice, while reversing epigenetic age by over 3 months. In macaques, EVABPC treatment was also neuroprotective, reduced inflammation, improved locomotor function and reduced epigenetic age by over 2 years. Our findings position ABPCs as an emerging and practical source of EVs with translational value for healthy aging interventions.

Inspired by the regenerative capacity of deer antlers, Hao and colleagues report that antler blastema progenitor cell-derived extracellular vesicle treatment counteracts bone loss and epigenetic aging and is neuroprotective in mice and macaques.

This Stem Cell Treatment Could One Day Make Insulin Obsolete

Type I diabetes is an exhausting full-time job. Having it means living a life full of constant care and maintenance. You’re always checking in on your blood sugar to make sure it isn’t too high or is it too low, extremes that could be easily reached with the most minor indulgence or tiniest bout of laziness.

A new treatment, as detailed in the New York Times, might change everything we know about managing type I diabetes.

Zimislecel is an experimental stem cell-based therapy that recently dropped a bomb on the diabetes world. Developed by the Boston-based Vertex Pharmaceuticals, it’s a one-time infusion that has turned 10 of 12 trial patients suffering from severe type I diabetes into people who no longer need insulin, and in less than a year.